This review was conducted to nd the e ectiveness and safety of ketamine in managing acute or sudden pain in the emergency scenarios. The research was carried out using databases such as PubMed, MEDLINE, Cochrane trial registries, and EMBASE from inception up to July 2022. The meta-analysis employed using the random-e ects model and presented results as pooled standardised mean di erence (SMD) and risk ratio (RR) alongside their 95% con dence intervals (CIs). The pooled SMD for pain assessment within 15 minutes stood at -0.72 (95% CI: -1.55 to 0.12). At 30 minutes, SMD was -0.27 (95% CI: -0.48 to -0.05), and by 45 minutes, it was -0.04 (95% CI: -0.26 to 0.18). Between the 45-minute and 60-minute mark, the SMD was -0.03 (95% CI: -0.22 to 0.17), and after the 60minute interval, it was registered at 0.11 (95% CI: -0.10 to 0.22). Pooled RR re ecting the requirement for supplementary analgaesics was 0.96 (95% CI: 0.65-1.41). The study found that ketamine's e cacy and safety were comparable or even superior to opioids in addressing sudden pain in the emergency contexts.